US Moxa Market: What Public Data Shows

Compare dated US acupuncture workforce, adult-use and Medicare indicators without treating them as moxa sales. Validate one SKU with buyer inquiries, samples and reorders.

How many US acupuncture practitioners did dated sources count?

Two credible, checkable data points define the professional channel:

• The American Society of Acupuncturists (ASA) and the NCCAOM — the profession’s own national bodies — state that they represent over 33,000 acupuncturists across the United States, in their April 2025 letter to the Secretary of Health and Human Services [1].
• A peer-reviewed workforce study published in the Journal of Integrative Medicine (2024) counted 34,524 active licensed acupuncturists as of January 1, 2023 (33,364 after removing multi-state license duplication), across 48 jurisdictions with acupuncture practice laws [2].

The same study carries a detail most promotional market write-ups omit: the licensed workforce was 8.87% lower than in 2018, a change the authors associate with the COVID-19 pandemic’s impact on the profession [2]. This compares two workforce snapshots; it does not prove a continuing annual decline. The base is large and institutionalized, but a sourcing plan built on “the practitioner count grows every year” would still contradict the cited evidence.

Geographic concentration matters for channel planning: California (7,317 licensees, 21.19% of the national total), New York (5,024, 14.55%), and Florida (2,644, 7.66%) are the three largest practitioner states [2]. The study also counted 56 accredited schools and 147 programs in its 2023 snapshot [2]. Neither count establishes current practitioner purchasing or moxa demand.

What does adult acupuncture use tell a moxa buyer?

The National Center for Complementary and Integrative Health (NCCIH, part of NIH) reports that US adult use of acupuncture rose from 1.0% in 2002 to 2.2% in 2022, based on National Health Interview Survey (NHIS) data [3]. NCCIH also notes that in the US, acupuncture is most commonly used for pain — back, joint, or neck pain [3].

The primary JAMA study, available through PubMed Central, reports that use of any of seven tracked complementary approaches rose from 19.2% (2002) to 36.7% (2022); among users, the share reporting use for pain management rose from 42.3% to 49.2% [4]. Those broader figures are not acupuncture-only or moxa figures. The authors note survey response, recall and cross-sectional limits [4], so do not turn them into a purchase forecast.

What does Medicare cover, and what does it leave unknown?

Since January 21, 2020, Medicare covers acupuncture for chronic low back pain: up to 12 visits in 90 days, 8 additional sessions for patients demonstrating improvement, maximum 20 treatments per year [5][6]. The current national coverage determination states the same defined benefit and its provider conditions [6].

Read this signal with precision, because the limits are as informative as the coverage:

1. The source is about acupuncture coverage, not moxa purchasing. It does not measure moxa demand, establish reimbursement for a particular moxibustion service, or determine a product’s market route [5].
2. Billing rules require a separate current review. The cited CMS material has a defined coverage scope and provider conditions. Do not use this article as a billing or reimbursement determination [5][6].

The correct inference is narrow: the 2020 decision is a federal coverage document with a defined scope. It is not evidence of moxa demand growth, moxa reimbursement, or a moxa procurement forecast.

Which public indicators can guide a first channel test?

The source dates and denominators matter more than a single headline number:

Three practical readings, all consistent with the sources above:

• The licensed channel is real and geographically concentrated. The workforce data identifies where practitioner outreach, buyer interviews, and pilot sampling can be prioritized [1][2]. It does not show which practitioners buy moxa, how often they reorder, or which formats they prefer.
• Consumer-side acupuncture usage is indirect context only. Rising acupuncture usage [3][4] is not moxa unit volume and should not set inventory or sales targets.
• Ask what a market-size figure measures. The sources here contain no audited moxa unit-volume or purchase-frequency denominator. Review any commercial estimate’s scope, date and method before using it to set inventory; keep an unverified figure out of a purchase commitment.

How can a buyer measure actual moxa demand?

Public indicators tell you that a channel exists; they cannot tell you whether your offer converts. Build a small, private evidence base before setting inventory:

1. First-party search data. Where Search Console has enough qualified impressions and clicks, review the exact buyer questions and destination URLs. Search appearance is an inquiry signal, not a measured moxa order or market volume.
2. Inquiry language. The exact questions buyers send before ordering (about smoke, ratios, sizes, documentation) are demand data. Track them; recurring questions become both product decisions and content.
3. Sample-to-order and reorder conversion. Record which approved samples become first orders and which first orders reorder, separated by SKU and channel. This is direct evidence for your line; it is not a claim about the whole market.

The cited public evidence does not establish an addressable moxa volume for this offer. Treat the data above as a channel-screening input, then set quantities only after your own buyer, sample, and reorder evidence exists.

For a first US test, define one buyer segment, one product problem and one measurable offer rather than ordering broadly against a dated national practitioner count. For example, MB2B-0001 is an 18 × 200 mm roll sourcing reference with a 10-roll box [7]; confirm its selected sample and commercial terms before using it in an outreach or quote. Record contacted accounts, qualified replies, sample requests, approved samples, first orders and reorders as separate stages. A state with many licensees can justify where to test; only your own conversion and reorder evidence can justify inventory.